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Introduction
Chronic myelomonocytic leukemia (CMML) is a malignant
hematologic disease of the elderly characterized by peripher-
al blood monocytosis, overproduction of bone marrow
monocytes with dysplasia of one or more lineages, and less
than 20% of blasts in the bone marrow. Its prognosis is poor
with a median survival of 12-18 months and a 15-20% risk of
transformation into acute myeloid leukemia (AML).1,2 CMML
is classified by the World Health Organization (WHO) into
the myelodysplastic/myeloproliferative neoplasms and,
based on the number of blasts, subclassified into CMML1
and CMML2 (5-9% and 10-19%, respectively).3 Like
myelodysplastic syndromes (MDS), CMML shows dysplastic
features that reflect ineffective hematopoiesis; however, dys-
plasia is associated with bone marrow proliferation.4,5
Because of this duality, CMML had been separated into a
myeloproliferative form (MP-CMML) and a myelodysplastic
form (MD-CMML) based on a semi-arbitrary threshold of 13
x 109/L for peripheral white blood cell (WBC).6 However, due
to its lack of impact on outcome, this separation is not includ-
ed in the WHO classification.3 Yet, the prognosis of MD-
CMML but not MP-CMML may be evaluated by the interna-
tional prognostic scoring system, underlining a similarity of
MD-CMML with MDS. Moreover, even if, given the limited
treatments currently available, MD and MP-CMMLs have
similar outcome, this situation may change with the advent
of new therapies, in which case they would each need to be
recognized separately. 
Because CMML has both dysplastic and proliferative fea-
tures it is likely that the disease is heterogeneous. We wanted
to determine whether these MD and MP features may have
any relevant molecular basis that may help classify and
understand CMML. To this aim, we established the gene
expression profiles and the mutational status of CMML and
compared them to those of MDS.
Design and Methods
Patients and samples
We selected 53 CMML and 32 MDS bone marrow (BM) samples
previously studied by array-comparative genome hybridization
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Chronic myelomonocytic leukemia is similar to but a separate entity from both myeloproliferative neoplasms and
myelodysplastic syndromes, and shows either myeloproliferative or myelodysplastic features. We ask whether this
distinction may have a molecular basis. We established the gene expression profiles of 39 samples of chronic
myelomonocytic leukemia (including 12 CD34-positive) and 32 CD34-positive samples of myelodysplastic syn-
dromes by using Affymetrix microarrays, and studied the status of 18 genes by Sanger sequencing and array-com-
parative genomic hybridization in 53 samples. Analysis of 12 mRNAS from chronic myelomonocytic leukemia
established a gene expression signature of 122 probe sets differentially expressed between proliferative and dysplas-
tic cases of chronic myelomonocytic leukemia. As compared to proliferative cases, dysplastic cases over-expressed
genes involved in red blood cell biology. When applied to 32 myelodysplastic syndromes, this gene expression sig-
nature was able to discriminate refractory anemias with ring sideroblasts from refractory anemias with excess of
blasts. By comparing mRNAS from these two forms of myelodysplastic syndromes we derived a second gene
expression signature. This signature separated the myelodysplastic and myeloproliferative forms of chronic
myelomonocytic leukemias. These results were validated using two independent gene expression data sets. We
found that myelodysplastic chronic myelomonocytic leukemias are characterized by mutations in transcription/epi-
genetic regulators (ASXL1, RUNX1, TET2) and splicing genes (SRSF2) and the absence of mutations in signaling
genes. Myelodysplastic chronic myelomonocytic leukemias and refractory anemias with ring sideroblasts share a
common expression program suggesting they are part of a continuum, which is not totally explained by their similar
but not, however, identical mutation spectrum.
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ABSTRACT
(aCGH) and sequencing of candidate genes.7,8 According to the
French-American-British (FAB)6 and WHO3 classifications, the
CMML series was made up of 31 MP and 22 MD cases (Online
Supplementary Table S1) and the MDS panel 8 refractory anemia
(RA) with ring sideroblasts (RARS), 13 RA with excess of blasts
type 1 (RAEB1) and 11 RAEB type 2 (RAEB2). CMML and MDS
cases selected for gene expression profiling were collected at the
time of diagnosis or in therapeutic abstention; none had been
treated. All patients signed an informed consent for research and
the study was approved by our institutional review board
("Comité d'Orientation Scientifique" of the Institut Paoli-
Calmettes).
CD34 enrichment
Samples were enriched in CD34-positive (CD34+) cells for 12
CMML and 32 MDS cases. Leukocytes were obtained after bone
marrow red cell lysis and washing with PBS, and labeled with
magnetic bead-conjugated anti-CD34 monoclonal antibody
(AC34 MicroBead; Miltenyi Biotec, Auburn, CA, USA). CD34+
hematopoietic stem cell populations were then purified through a
miniMACS magnetic cell separation column (Miltenyi Biotec).
RNA/DNA extraction
RNAs and DNAs were extracted from whole BM CMML sam-
ples. After BM aspiration, a red cell lysis was carried out, followed
by rinses with PBS. Leukocytes were processed immediately or
cryopreserved at –80°C at the sample bank of the Institute and
processed later. DNA and RNA were extracted using Nucleobond
RNA/DNA kit from Macherey-Nagel (Düren, Germany) as recom-
mended by the supplier. RNA from CD34+ cells were similarly
extracted using Nucleobond RNA/DNA kit from Macherey-Nagel.
Sequencing of 18 candidate genes
Mutations in ASXL1 (exon 12), CBL (exons 8, 9), DNMT3A
(exons 15-23), EZH2 (all exons), FLT3 (exons 14, 15, 20), IDH1/2
(exons 4), JAK2 (exon 14), NF1 (exons 1-50), N/KRAS (exons 1, 2),
PTPN11 (exons 3, 11) ), RUNX1 (exons 1-8), SF3B1 (exons 12-16),
SUZ12 (exons 14-16), SRSF2 (exon 2), TET2 (exons 3-11),
U2AF35/U2AF1 (exons 2, 6), and ZRSR2 (exons 1-11) were ana-
lyzed using BM DNA as previously described.7-11
Gene expression profiling
Gene expression profiles of 39 CMML (out of the 53) and 32
MDS (all from CD34+ cells) mRNAs were established. Among the
39 CMML cases, 37 were studied as BM (10 of these were also
studied as CD34+) and 2 as CD34+ RNAs. In other words, 10
CMML samples were studied as both CD34+ and whole BM
RNAs, and 2 as CD34+ only (12 CD34+ in total). 
RNA quality and purity were assessed with Agilent Bioanalyzer
2100 (Agilent Technologies, Palo Alto, CA, USA). Preparation of
cRNA, hybridizations onto Affymetrix U133 Plus 2.0 human
oligonucleotide microarrays, washes and detection were carried
out as recommended by the supplier and as previously described.12
Data were analyzed by the Robust Multichip Average (RMA)
method in R using Bioconductor and associated package, as previ-
ously described.12 Before analysis, a first filtering process removed
from the data set the probe sets with low and poorly measured
expression as defined by an expression value inferior to 100 units,
thus retaining 19,730 probe sets in the 12 CMML CD34+ data set
and 23,515 probe sets in the 32 MDS CD34+ data set.
Before hierarchical clustering, a second filter, based on the inten-
sity of standard deviation (SD >0.5), was applied and retained
9179 probe sets in the 37 CMML from the whole BM data set,
12,660 probe sets in the 12 CMML CD34+ data set, and 11,623
probe sets in the 32 MDS CD34+ data set. Filtered data were then
log2-transformed and submitted to the Cluster program using data
median-centered on genes, Pearson’s correlation as similarity met-
rics and centroid linkage clustering. Results were shown using the
TreeView program.
Supervised analyses identified and ranked genes that discrimi-
nate two groups of samples. A discriminating score (DS) was cal-
culated for each of the 19,730 probe sets for the 12 CMML and of
the 23,515 probe sets for the 32 MDS.13 A ‘leave-one-out’ (LOO)
cross-validation procedure was applied to estimate the accuracy of
prediction of the signature and the validity of the supervised
analysis. Functional processes and pathways were identified using
Ingenuity software (Ingenuity Systems, Redwood City, CA, USA).
To test the performance of our signature on independent panels,
we analyzed publicly-available external data sets14,15 collected
from NCBI/Genbank GEO database (series entry GES4619 and
entry GES15061). Gene set enrichment analysis (GSEA) was car-
ried out as reported.16 Fisher’s exact test was used when appropri-
ate. All statistical tests were two-sided at the 5% level of signifi-
cance. All statistical analyses were carried out in R (2.8.0) and its
associated packages.
Results 
Gene expression analysis separates MD- from 
MP-CMML cases
We first determined the gene expression profiles of 37
BM CMML samples. Unsupervised analysis identified two
clusters (S1 and S2) including 17 and 20 cases, respectively
(Online Supplementary Figure S1). S1 and S2 cases did not
correlate with clinical or hematologic data and were not
separated according to MD/MP features. We next deter-
mined the gene expression profiles of 12 available RNAs
from CD34+ CMML samples (5 MD and 7 MP).
Hierarchical clustering separated the 12 samples into two
clusters (Online Supplementary Figure S2). The two clusters
differed (Fisher’s exact test, P=0.04) in terms of leukocyto-
sis and overlapped the MP/MD definition: the left cluster
contained 4 of 5 MD-CMML cases whereas the right clus-
ter comprised 6 of 7 MP-CMML cases (black boxes). This
showed that the MD/MP distinction has a molecular basis
at the transcriptional level on a whole-genome scale.
MD-CMML over-expresses genes involved in red blood
cell biology as compared to MP-CMML
To understand this MD/MP difference, we compared
the gene expression profiles from the 5 MD-CMML sam-
ples to those of the 7 MP-CMML samples in a supervised
analysis. A total of 122 probe sets (corresponding to 96
unique genes and 6 ESTs; Online Supplementary Table S2)
were differentially expressed between the two forms. The
accuracy of prediction and validity of our procedure was
cross validated by LOO with overall accuracy of 92%
(Fisher’s exact test, P=0.015) with high sensitivity and
specificity (86% and 100%; only one MP-CMML was
misplaced) and with a theoretical number of false positive
of 30.
Among the 122 probe sets, 61 were up-regulated and 61
were down-regulated in the MP samples (the top 20 up-
regulated genes are listed in the Online Supplementary Table
S3). Inspection of the list (hereafter called MD/MP CMML
gene expression signature or CMML GES) showed that
up-regulated genes in MD-CMML belonged to pathways
and cell processes found in red blood cells: they encoded
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enzymes involved in heme synthesis (ALAS2, HMBS,
FECH), glycophorins (GYPA, GYPB), globins (HBA1, HBB,
HBM), and proteins associated with blood groups (RHD,
RHCE) and erythrocyte differentiation (TRIM10).
Ingenuity analysis of this GES confirmed that the most rel-
evant over-expressed genes in MD-CMML cases were
involved in erythropoiesis (data not shown). Down-regulat-
ed genes in MD-CMML included ZCCHC11/TUT4, PHC1
and BMI1.
We applied this CMML GES to our 12 CD34+ CMML
RNAs. As expected, the MD and MP samples were sepa-
rated (Fisher’s exact test, P=1x10-3) (Figure 1A). We applied
this GES to the 37 BM CMML RNAs (including 10 of the
10 CD34+ samples and 27 additional samples). Two clus-
ters were observed: in the left cluster, 16 of the 19 samples
were MP-CMML, whereas in the right cluster, 13 of the 18
samples were MD-CMML (Figure 1B), supporting the
validity of our MD/MP CMML GES (Fisher’s exact test;
V. Gelsi-Boyer et al.
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Figure 1. Classification of CMML (A, B) and MDS samples (D, E) using a CMML gene expression signature. (A) Hierarchical clustering of 12
CD34+ CMML RNAs with the 122-gene MD/MP CMML gene expression signature (GES). Each row of the data matrix represents a gene and
each column represents a sample. Expression levels are depicted according to the color scale shown at the bottom. Red and green indicate
expression levels respectively above and below the median. The magnitude of deviation from the median is represented by the color satu-
ration. Below the horizontal sample dendrogram, are some histoclinical and molecular features of the samples (PLT: platelets), including the
MD or MP phenotype (white for MP and black for MD). The GES (vertical dendrogram) classifies the samples into two clusters (black vertical
line) associated with the MD/MP definition. The correlation of the two clusters with the histoclinical data is indicated using the P value of
Fisher’s exact test to the right of the stripes (significant P-values are in blue). (B) Similar to (A), but applied to 37 bone marrow CMML sam-
ples. The genes are not clustered and are ordered as in (A). (C) Hierarchical clustering of 32 CD34+ MDS samples using the 122-gene MD/MP
CMML gene expression signature (GES). Legend as in (A). RARS and RAEB are indicated by colored boxes under the dendrogram. The GES
significantly distinguishes the RARS from the RAEB samples. (D) As in (C), but applied to the 32 mRNAs from CD34-positive MDS samples
and 12 mRNAs from CD34-positive CMML samples. The genes are not clustered and are ordered as in (A). The CMML GES separates the
RARS and MD-CMML samples from the MP-CMML and RAEB samples. MD/MP forms are indicated by black and white boxes as indicated. 
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P=6x10-4). Using GSEA, we confronted the gene expres-
sion profiles of our 37 BM CMML mRNAs to the 122 gene
signature. We found a significant enrichment in the red
cell genes of this signature in the MD-CMML samples
(Enrichment Score=0.76; Normalized Enrichment
Score=2.08; FDR q-value<0.01).
CMML gene expression signature classifies MDS 
samples 
Overexpression of genes involved in red cell biology has
been observed in previous gene expression analyses of
RARS samples.14,17 When applied to our 32 CD34+ MDS
samples, the CMML GES perfectly separated RARS from
RAEB samples (Fisher’s exact test, P=1x10-4, Figure 1C).
When the CMML GES was applied to the pool of 12
CMML and 32 MDS CD34+ samples the MD-CMMLs
clustered with the RARS samples and the MP-CMMLs
with the RAEB samples (Figure 1D) (Fisher’s exact test,
P=1.8x10-7). These results showed that MD-CMML and
RARS share gene similar expression programs.
MDS gene expression signature classifies CMML 
samples
Then we derived an MDS GES by comparing the gene
expression profiles of our 8 RARS to those of our 24 RAEB
samples. A total of 428 probe sets (295 unique genes and
25 ESTs; Online Supplementary Table S4) were differentially
expressed between RARS and RAEB (hereafter called
MDS GES). The accuracy of prediction and validity of our
procedure was cross-validated by LOO with overall accu-
racy of 78% (Fisher’s exact test, P=6x10-4) with high sensi-
tivity and specificity (72% and 100%, respectively) and
with a theoretical number of false positive of 5.
A total of 304 probe sets were up-regulated and 124
were down-regulated in the RARS cases (the top 20 up-
regulated genes are listed in Online Supplementary Table
S3). Up-regulated genes in RARS belonged to the pathway
and cell processes found in red blood cells (Online
Supplementary Figure S3): they encoded proteins involved
in heme synthesis (ALAS2, ALAD, HMBS, UROD, CPOX,
PPOX, FECH), iron-sulfur cluster biogenesis (SLC25A37,
GLRX5), mitochondrial biology (TRAK2), antioxidant
defense (HAGH), glycophorins (GYPA, GYPB, GYPE), glo-
bins (HBA1, HBA2, HBB, HBD, HBG1, HBM, HBQ1), pro-
teins associated with blood groups (RHCE, RHD, DARC,
KEL), red cell structure (ANK1, EPB42, EPB49, ERMAP,
SPTA1, SLC4A1), differentiation (TRIM10) and regulation
(GATA1, KLF1, TAL1, EPOR). Ingenuity analysis of this
GES confirmed that the most relevant over-expressed
genes in RARS were involved in erythropoiesis (data not
shown). When applied to our 32 CD34+ MDS RNAs, the
MDS GES perfectly separated the RARS from the RAEB
samples (Figure 2A), as expected. More surprisingly, when
applied to the 12 CD34+ (Figure 2B) or BM CMML mRNAs
(Fisher’s exact test, P=8.4.10-4; data not shown) it perfectly
separated the MD-CMML from the MP-CMML samples.
Thus, MD-CMML and RARS share expression of genes
involved in erythropoiesis and red blood cell biology, with
a total of 38 probe sets corresponding to 25 unique genes
common to the MD/MP CMML and MDS GESs (Online
Supplementary Table S3).
External validation on two independent data sets 
To validate these unexpected results, we applied our
two GESs (CMML GES and MDS GES) to two external
published data sets (a CMML and an MDS data set)14,15 and
a GES obtained from one of these external data sets to our
CMML and MDS samples.
First, we studied the external data sets with our two
GESs. The first data set corresponded to the expression
profiles of 25 CMML BM samples profiled using
Affymetrix microarrays.15 Unfortunately, information on
MD/MP forms was not associated with the data. Our
CMML GES separated these external CMML cases into
two groups, one of which over-expressed red blood cell
genes (Online Supplementary Figure S4A, stripe 1). All but
one of the 25 CMML samples was similarly sorted with
our MDS GES (Online Supplementary Figure S4B, stripe 2).
We studied a second external data set, consisting in the
expression profiles of 66 CD34+ MDS samples studied by
Affymetrix microarrays.14 Our MDS GES separated the
RARS from the other MDS classes (Figure 3A), as did our
CMML GES (Figure 3B).
Second, we derived a third GES (hereafter called MDS-
ext GES) by comparing RARS and RAEB samples from the
MDS external data set.14 This MDS-ext GES contained 738
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Figure 2. Classification of MDS samples using an MDS gene expres-
sion signature. (A) Hierarchical clustering of 32 CD34+ MDS sam-
ples using the 428-gene MDS gene expression signature. Legend as
in Figure 1A. MDS classes are indicated by colored boxes in the
stripe under the dendrogram. The GES significantly distinguishes
the RARS from the RAEB samples. (B) As in (A), but applied to the
12 CD34-positive CMML samples. The genes are not clustered and
are ordered as in (A). The GES significantly distinguishes the MD
from the M¨-CMML samples. MD/MP forms are indicated by white
and black boxes in the stripe under the dendrogram. 
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probe sets (597 unique genes and 28 ESTs). The genes
found over-expressed in RARS are involved in red blood
cell biology. This GES was able to separate our RARS from
RAEB samples (Online Supplementary Figure S4C) and our
MD-CMML from MP-CMML CD34-positive samples
(Figure 3C). When applied to the CMML external data
set,15 it separated the 25 samples (stripe 3) in the same way
as did our CMML and MDS GESs (Online Supplementary
Figure S4D).
Thus, GESs obtained from comparison from either
CMML or MDS were similarly able to distinguish CMML
and MDS classes, showing that MD-CMML and RARS
share common molecular features. The CMML GES, MDS
GES and MDS-ext GES had 26 probe sets in common (cor-
responding to 16 genes and 1 EST)(Figure 3D), all overex-
pressed in MD-CMML and RARS and involved in red cell
biology (Online Supplementary Table S3). This small core
GES separated MD-CMML from MP-CMML (Figure 3E)
and RARS from RAEB (Online Supplementary Figure S5) as
efficiently as the three larger GESs.
Analysis of mutated genes in CMML and MDS 
These results showed a molecular similarity between
MD-CMML and RARS. Could this similarity be the result
of gene mutations common and specific to the two dis-
eases? We7,8,18 and others19-36 have previously studied sever-
al leukemogenic genes in CMML and RARS. However,
several of those (e.g. ASXL1, RUNX1, TET2) are neither
specific of MD-CMML nor of RARS and, therefore, can
account neither for the similarity between the two dis-
eases nor for the differences from the other myeloid
malignancies. 
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Figure 3. Independent validation of the gene expression signatures. (A) Hierarchical clustering of 66 Pellagatti’s CD34+ MDS external sam-
ples14 using our 428-gene MDS GES. Legend similar to Figure 1A. MDS classes are indicated by colored boxes in the stripe under the den-
drogram. The GES significantly separates the RARS from the other MDS classes. (B) Similar to (A), but using our 122-gene MD/MP CMML.
The GES significantly separates the RARS from the other MDS classes. (C) Hierarchical clustering of our 12 CD34-positive CMML samples
using the MDS-ext GES. MD/MP forms are indicated by black and white boxes in the stripe under the dendrogram. The GES significantly
separates the MD-CMML samples from the MP-CMML samples. (D) Venn diagram showing the overlap between the three GES: 26 genes
overlap the three GES. (E) Hierarchical clustering of the 12 mRNAs from CD34+ CMML samples using these 26 overlapping genes. This 26-
gene GES separates the MD-CMML from the MP-CMML samples.
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We studied the sequence of 18 genes involved in the reg-
ulation of transcription (ASXL1, DNMT3A, EZH2, IDH1,
IDH2, RUNX1, SUZ12, TET2), splicing (SF3B1, SRSF2,
U2AF1, ZRSR2) and signaling (CBL, FLT3, JAK2, KRAS,
NRAS, PTPN11) in our series of 53 CMMLs. Results are
shown in Figure 4, Online Supplementary Table S5 (see also
Online Supplementary Figure S1). The samples had been
studied by aCGH7,18 and deletions of these genes were
taken into account when appropriate. In CMML, splicing
mutations have been recently described,31 but how muta-
tions in 4 splicing genes combine with alterations in the
other 14 genes has not yet been reported.  Only seven
samples (3 MD and 4 MP) did not show any mutation in
the genes studied (13%). Among transcription/epigenetic
regulators, ASXL1, RUNX1 and TET2 were the most fre-
quently mutated genes. 
Mutations in these genes were found in both MP and
MD cases. DNMT3A mutations were only found in MD-
CMML and EZH2mutations in MP-CMML; however, the
number of these events was low, confirming findings of
previous studies.27-30 MD-CMML showed only one CBL
mutation and one NF1 deletion, whereas MP-CMML
showed 14 mutations in signaling genes and one NF1 dele-
tion. Thus, mutations in these selected signaling genes
account for a first difference between MD-CMML and
MP-CMML. 
Except in one case, mutations in splicing genes were
mutually exclusive, as previously described31 and recently
reviewed.37 We found one mutation in SF3B1, 3 in U2AF1,
2 in ZRSF2 and 24 in SRSF2. In total, 15 of 22 (68%) MD
and 15 of 31 (45%) MP cases were mutated in the splicing
genes studied. They were not differentially distributed
between the two forms (P=0.17): the 22 MD cases
showed no SF3B1 and 13 SRSF2 mutations (59%) where-
as the 31 MP cases showed one SF3B1 and 11 SRSF2
mutations (38.7%). In addition, U2AF1 and ZRSR2 were
mutated in one and one MD-CMML cases and in 2 and
one MP-CMML cases, respectively. 
To evaluate the possible relationships between gene
mutations and gene expression we looked at the expres-
sion of the mutated genes (Online Supplementary Figure
S2B). As expected, since they were not found in the GES,
there was no difference in expression of the 18 genes
between MD and MP-CMML. Gene mutations in our
series of MDS cases have been described in previous stud-
ies7,8,11 and will not be detailed here again except for the
sake of comparison with CMML. We found 6 mutations
in SF3B1 and 3 in SRSF2 in our series of 32 MDSs (Online
Supplementary Table S6). They were differentially distrib-
uted between RARS and RAEB cases: the 8 RARS showed
5 SF3B1 and one SRSF2 mutations whereas the 24 RAEB
cases showed one SF3B1 and 2 SRSF2 mutations. Three
RAEB cases were also mutated in U2AF1 and ZRSR2.
Thus, both MD-CMML and RARS display frequent
mutations in genes encoding components of the RNA
splicing machinery. However, MP-CMML cases also show
alterations of this process. RARS and MD-CMML also
show more mutations in DNMT3A.38
Discussion 
We studied CMML by gene expression profiling and by
sequencing analyses of 18 candidate genes. Unsupervised
analysis of mRNAs from CD34-positive cells separated
CMML into two molecular subtypes that overlapped with
the MD and MP forms initially distinguished by the FAB
classification. Supervised analysis established an MD/MP
CMML GES characterized by the overexpression in MD-
CMML of genes involved in red blood cells. The compar-
ison of RARS and RAEB samples allowed the establish-
ment of an MDS GES that was also characterized by the
overexpression in RARS of the same genes and functions,
as observed in previous studies.14 The CMML GES recog-
nized the RARS and also the MDS GES recognized the
MD-CMML samples. Thus, MD-CMML and RARS share
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Figure 4. Gene mutations in CMML. Profiles of concomitant gene mutations of 18 genes in 53 CMML cases. Mutations in RARS (Online
Supplementary Table S6) are shown for comparison. The number of gene mutations per case is presented below. Missing data are indicated
by gray squares. 
Transcription
epigenetic
Splicing
Signaling
not done
not done
MP-CMML MD-CMML RARS
a similar transcriptional program involving red blood cell
homeostasis These results were validated by using two
external published data sets and a third GES (MDS-ext
GES) suggesting the robustness of the results. In MD-
CMML and RARS, several red blood cell functions were
affected, including heme biosynthesis, iron-sulfur cluster
biogenesis, calcium uptake, antioxidant defense, and tran-
scription regulation, suggesting that MD-CMML and
RARS share a common differentiation pathway character-
ized by an erythrocytic program. 
In MD-CMML and RARS these results could reflect a
mere abundance of erythroid progenitors, an overexpres-
sion of the program to compensate for abnormal red blood
cell maturation, or a true molecular defect with patholog-
ical consequences. This defect in MD-CMML and RARS
may be different or similar. In the latter case at least two
possibilities should be considered. First, genes present in
the signatures and/or involved in the identified functions
could be directly affected by mutations. Many of these
functions take place in the mitochondrion and it is possi-
ble that the defect affects primarily this organelle; the role
of the iron transporter gene ABCB7 had been suspected,
but the gene is not mutated.39 Actually, mutations in mito-
chondrion genes are associated with congenital rather
than acquired anemias. A second hypothesis is perhaps
the most likely. Mutations in splicing factors may indirect-
ly affect red cell processes by leading to abnormal process-
ing of mRNAs, including RNAs involved in red cell biolo-
gy.40 These frequently show alternative splicing41 which
may make them hypersensitive to splicing mutations.
SF3B1mutations are prominent in MDS with ring siderob-
lasts (RS) (a hallmark of iron overload and dyserythro-
poiesis) such as RARS, and SF3B1 haploinsufficiency or
inhibition leads to the formation of RS.42 In contrast,
SRSF2mutations are frequent in CMML.31 Splicing defects
in SRSF2 in CMML and in SF3B1 in RARS may affect
genes involved in erythropoiesis such as ABCB7, FTL,
GATA1, or HAMP for example, or a master transcription
factor of hematopoietic cell lineages such as TIF1γ, which
controls erythroid cell fate and acts as a tumor suppressor
in CMML.43-45 However, SRSF2 mutations are also found
in MP-CMML which does not show a red cell program.
MP-CMML is characterized by mutations in signaling
genes, and this could modify the effect of SRSF2.
Overexpression of components of the pathway may also
compensate for the defect (e.g. DICER1, CUGBP2/CELF2,
ZCCHC11/TUT4 and SYNCRIP which are involved in
miRNA and mRNA editing).
Current molecular findings are shedding new light on
myeloid diseases.46 Our study establishes a molecular
bridge between CMML and MDS, suggesting that these
diseases are part of a continuum of pathologies.
Interestingly, we (Online Supplementary Table S5, HD-0376)
and others47 have observed rare cases of passage from
MDS to CMML. This continuum is likely to include RARS
associated with marked thrombocytosis (RARS-T, a dis-
ease characterized by mutations in SF3B1 and JAK2 or
MPL), since RARS and RARS-T are characterized by com-
mon gene expression features48 and the presence of RS. No
such marker has been regularly described in CMML; nor
has it been systematically investigated either. Perhaps this
is due to a stronger defect in RARS than in MD-CMML
because mutations in SF3B1 have a stronger impact on
erythropoiesis than SRSF2.
We did not find a difference in overall survival between
our 37 MD and MP-CMML cases separated by the CMML
GES (P=0.18, Fisher’s exact test). Neither did SRSF2muta-
tion have any impact on prognosis. If, given the current
possibilities of treatment, the prognosis of MD and MP-
CMML is similar, in the future these diseases may be
treated differently and we will need to be able to identify
the difference between them. Our discovery of a molecu-
lar similarity between MD-CMML and RARS could be
useful by improving the classification of these diseases,
providing pathophysiological clues and suggesting the
possibility of using treatment approaches common to the
two diseases but different from those for MP-CMML.
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